

# Julie O'Neal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4679566/publications.pdf>

Version: 2024-02-01

16  
papers

549  
citations

1162367

8  
h-index

1125271

13  
g-index

16  
all docs

16  
docs citations

16  
times ranked

1017  
citing authors

#	ARTICLE	IF	CITATIONS
1	An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. <i>Leukemia</i> , 2018, 32, 1970-1983.	3.3	282
2	Co-evolution of tumor and immune cells during progression of multiple myeloma. <i>Nature Communications</i> , 2021, 12, 2559.	5.8	68
3	A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. <i>Blood Cancer Journal</i> , 2018, 8, 35.	2.8	41
4	A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity. <i>Nature Communications</i> , 2022, 13, .	5.8	29
5	Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy. <i>Leukemia</i> , 2021, 35, 2346-2357.	3.3	28
6	Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types. <i>PLoS ONE</i> , 2015, 10, e0127828.	1.1	26
7	VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival. <i>Clinical Cancer Research</i> , 2021, 27, 1974-1986.	3.2	17
8	CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells. <i>Leukemia</i> , 2022, 36, 1625-1634.	3.3	15
9	Chimeric Antigen Receptor T Cells Specific for CLL-1 for Treatment of Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2205-2205.	0.6	13
10	Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival. <i>Scientific Reports</i> , 2022, 12, 30.	1.6	12
11	Deletion of Rb1 induces both hyperproliferation and cell death in murine germinal center B cells. <i>Experimental Hematology</i> , 2016, 44, 161-165.e4.	0.2	9
12	Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1302-1311.	3.3	8
13	Single-Cell Transcriptomic and Proteomic Diversity in Multiple Myeloma. <i>Blood</i> , 2019, 134, 5531-5531.	0.6	1
14	Myeloproliferative Disease Induced by TEL-PDGFRB Displays Dynamic Range Sensitivity to Stat5 Gene Dosage in Mice.. <i>Blood</i> , 2006, 108, 3620-3620.	0.6	0
15	Single-Cell Pathway Enrichment and Regulatory Profiling of Multiple Myeloma across Disease Stages. <i>Blood</i> , 2019, 134, 364-364.	0.6	0
16	Myeloma Cell Associated Therapeutic Protein Discovery Using Single Cell RNA-Seq Data. <i>Blood</i> , 2020, 136, 4-5.	0.6	0